RADO
Asset Logo

Radiopharm Theranostics Limited

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Radiopharm Theranostics Limited - Option Expiring 30-Nov-2026

📈 Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.05

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in RADO

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in RADO

N/A
RADO investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in RADO also invest in...

Want more shares? Try these...

Ragnar Metals Limited

RAG

Ragnar Metals Ltd. engages in the exploration, evaluation, and development of nickel, gold, silver, and base metals projects. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-03-31. The firm is engaged in the exploration and evaluation of its projects in Scandinavia and commencement of the exploration and evaluation of its Australian projects. Its projects include Granmuren Nickel prospect, Gaddebo project, Leeds project and Kenya project. The Granmuren Nickel prospect is its greenfield nickel, copper and cobalt discovery in the heart of the Bergslagen district of Sweden. The Gaddebo project is located approximately 15 kilometers (km) southeast of the town of Sala and approximately 21 km east-southeast of the Granmuren deposit. The Leeds project is located on the Norseman Wiluna greenstone belt approximately 20 km south of the Goldfields St. Ives Mining Camp at Kambalda, and comprises two granted prospecting licenses. The Kenya project is located approximately 50 km along strike to the south of AngloGold Ashanti’s Sunrise Dam gold mining camp in the Laverton gold mining district.

📊 Share price

$0.02 AUD
Find Out More

Range International Ltd. is a manufacturer of plastic pallets, which develops the ThermoFusion technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-22. The firm operates in two segments, being the manufacture and sale of plastic pallets and the manufacture and sale of plastic fencing. In Indonesia, its ThermoFusion technology allows the Company to make plastic pallets from 100% recycled mixed waste plastic. In Australia, the Company manufactures plastic fencing and retaining wall panels from recycled plastic. The firm has production lines operating in its East Java factory in Indonesia and sells its pallets under the brand Re>Pal, supplying pallets throughout Indonesia and across Asia. The Company’s Indonesian manufacturing business produces pallets from mixed waste plastic. The Company’s pilot plant in Cairns is engaged in the production of its fencing and retaining wall products from recycled plastic.

📊 Share price

$0.01 AUD

Race Oncology Ltd. is a precision oncology company, which engages in the discovery and development of the phase 2/3 cancer drug called Zantrene. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The firm is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The firm also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.

📊 Share price

$1.51 AUD

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology. The Company’s subsidiary includes Radiopharm Theranostics (USA) Inc. The firm has a pipeline of four licensed platform technologies, Nano-monoclonal antibodies (mAbs), Pivalate, AVβ6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, RAD201, RAD202, RAD204, RAD205, RAD207, RAD301, RAD302, RAD401 and RAD402.

📊 Share price

$0.15 AUD
Compare
Add to watchlist